Entities / Company
Lipocine (United States).
company in Salt Lake City, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 12
What's happening
Gone quiet
No new reports in 90+ days-
Lipocine is developing LPCN 1154 for Postpartum Depression (PPD) treatment, with trials seeking FDA approval. The development involves expertise from NIH and affiliated centers like Northwell Health.Speculative1 report
-
The FDA granted guidance on June 27, 2025, allowing outpatient setting for clinical trials involving Lipocine in the United States.Speculative1 report1 development inside
-
Lipocine's study followed FDA feedback regarding its clinical trials.Speculative1 report
-
Lipocine presented at H.C. Wainwright conference on September 6, 2025.Some support1 report1 development inside
-
Lipocine management reviewed the treatment landscape at a specific event hosted by Northwell Health on August 5, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Lipocine (United States) this week
News at the entities that move Lipocine (United States) most-
Mahesh Patel StructuralMahesh Patel is the director of Green City, an estate operating within the Abia area.Moves Lipocine (United States)
-
FDA StructuralReplimune Group, Inc. received accelerated approval for TUDRIQEV™ in advanced melanoma, while its stock price reflected quarterly EPS misses.Moves Lipocine (United States)
Connections
The 2 strongest of 12, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Mahesh Patel Structural
Mahesh Patel serves as the CEO of Lipocine.
-
FDA Structural
Lipocine's clinical trials are subject to regulatory oversight, feedback, and approval by the FDA.
History
Events by the month they beganJune 2026
5 events- Lipocine is developing LPCN 1154 for Postpartum Depression (PPD) treatment, with trials seeking FDA approval. The development involves expertise from NIH and affiliated centers like Northwell Health.
- The FDA granted guidance on June 27, 2025, allowing outpatient setting for clinical trials involving Lipocine in the United States.
- Lipocine's study followed FDA feedback regarding its clinical trials.
- Lipocine presented at H.C. Wainwright conference on September 6, 2025.
- Lipocine management reviewed the treatment landscape at a specific event hosted by Northwell Health on August 5, 2025.